Research Study Summary
A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)
The purpose of this investigation is to demonstrate the safety and effectiveness of Lower Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled study. After the implant procedure, subjects will be randomized to either the Treatment Group (immediate stimulation) or Control Group (delayed stimulation) for six months followed by an additional open-label phase in which all subjects will receive electrical stimulation. Subjects continue on stimulation treatment in an extended open-label follow-up phase through 5 years post-stimulation.
To Learn more
CW ID: 222921
Date Last Changed:
February 3, 2017
Clinical Trial Snapshot
- Both Male and Female
- 22 and up
- Overall Status
- EndoStim Inc.
- Facility Type
- Able and willing to provide written informed consent
- Able and willing to comply with required study procedures and follow-up schedule
- 22 - 75 years of age at the time of informed consent
- Documented symptoms of gastroesophageal reflux disease (GERD) for longer than 6 months (regurgitation and heartburn which is defined as burning epigastric or substernal pain which responds to acid neutralization or suppression) which requires daily use of proton pump inhibitors (PPIs) or other anti-reflux drug therapy, who continue to have symptoms despite maximum medical therapy or are "intolerant" -severe side-effects (e.g. anaphylaxis or severe allergic reaction, recurrent C. difficile, severe hypomagnesaemia) to one PPI or mild/moderate side effect (e.g. nausea, vomiting, diarrhea or abdominal pain) to at least 2 PPIs of different chemical classes.
- Symptomatic improvement on PPI therapy demonstrated by a composite GERD-health-related quality of life (HRQL) score of =20 off PPI, and a =10 point improvement on PPI compared to the off PPI composite GERD-HRQL score.
- Excessive lower esophageal acid exposure during pH monitoring (defined as distal esophageal pH < 4 for > 6.0% of the monitoring time) performed after at least 5 days off of PPIs and at least 2 days off of H2 blockers. At least 18 hour of esophageal pH recording will be considered adequate.
- Esophagitis = Grade B (Los Angeles (LA) classification) as measured by upper endoscopy off PPI for 10-14 days
- Resting LES end expiratory pressure = 5mm Hg as measured by high resolution manometry (HRM) performed within 6 months of enrollment
- Esophageal body contraction amplitude > 30 mmHg for > 30% of swallows and > 30% peristaltic contractions on HRM.
- Suitable surgical candidate able to undergo general anesthesia and laparoscopic surgery
- Previous EndoStim LES System implant and/or implant attempt
- Previous surgery involving the gastroesophageal junction or the lead implant site, such as a Nissen fundoplication
- Previous endoscopic intervention for the treatment of GERD and/or Barrett's esophagus
- Hiatal hernia larger than 2 cm as determined by endoscopy
- History of gastroparesis
- Any non-GERD esophageal motility disorders that in the opinion of investigator precludes an anti-reflux procedure
- History of or known esophageal stricture or significant esophageal anatomic abnormalities (obstructive lesions, etc.)
- Barrett's epithelium or any grade of dysplasia
- Documented history of esophagitis Grade C or D (LA Classification)
- History of suspected or confirmed esophageal or gastric cancer
- Esophageal or gastric varices
- Symptoms of dysphagia more than once per week every week within the last 3 months
- Unable to tolerate withdrawal from H2 Blockers or PPI medications
- Suspected or known allergies to titanium, platinum, iridium, stainless steel, silicone, epoxy, or nylon
- Body mass index (BMI) > 35 kg/m2
- Any significant multisystem diseases
- Autoimmune or a connective tissue disorder (scleroderma, dermatomyositis, Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome, etc.) requiring therapy in the preceding 2 years
- Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c > 9.5 in the previous 6 months or at screening/baseline
- Significant cardiac arrhythmia or ectopy or significant cardiovascular disease (i.e. unstable angina pectoris, hemodynamically significant valvular disease, severe congestive heart failure), or any cardiac therapeutic intervention within the last 6 months.
- Significant cerebrovascular event within the last 6 months
- Existing implanted electrical stimulator (pacemaker, implantable cardioverter defibrillator, deep brain stimulator (DBS), bone growth or pelvic floor stimulators, drug pumps, etc.)
- Female subject of child-bearing potential and is pregnant or nursing, or intends to become pregnant during the trial period, who is not using a reliable form of birth control
- Currently enrolled in other potentially confounding research
- Active infection as determined by the investigator
- History of any malignancy in the last 2 years
- Life expectancy less than 3 years aa. Diagnosed major psychiatric disorder (bipolar, schizophrenia, etc.) bb. Any condition that, at the discretion of the investigator or sponsor, would interfere with accurate interpretation of the study endpoints or preclude participation in the trial
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.